Cosmos Holdings Inc. (COSM): Business Model Canvas

In der dynamischen Landschaft der Innovationen im Gesundheitswesen erweist sich Cosmos Holdings Inc. (COSM) als transformative Kraft, die sich strategisch durch die komplexe Schnittstelle zwischen pharmazeutischer Forschung, Medizintechnik und modernsten Gesundheitslösungen bewegt. Durch die Nutzung eines umfassenden Business Model Canvas, das strategische Partnerschaften, fortschrittliche Forschungskapazitäten und vielfältige Einnahmequellen umfasst, definiert COSM neu, wie medizinische Innovationen systematisch entwickelt, kommerzialisiert und an globale Gesundheitsökosysteme bereitgestellt werden können. Ihr einzigartiger Ansatz vereint technologisches Können, wissenschaftliche Expertise und marktorientierte Strategien, um einen ganzheitlichen Rahmen zu schaffen, der die Entwicklung medizinischer Produkte und die Bereitstellung von Gesundheitsdienstleistungen zu revolutionieren verspricht.

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Allianz mit Pharmahändlern

Ab 2024 unterhält Cosmos Holdings Inc. strategische Partnerschaften mit den folgenden pharmazeutischen Vertriebsnetzwerken:

Vertriebspartner	Jahresvolumen	Dauer der Partnerschaft
McKesson Corporation	Pharmazeutische Produkte im Wert von 3,2 Millionen US-Dollar	5-Jahres-Vertrag
AmerisourceBergen	Pharmazeutischer Bestand im Wert von 2,7 Millionen US-Dollar	4-Jahres-Vertrag

Zusammenarbeit mit internationalen medizinischen Forschungseinrichtungen

Cosmos Holdings arbeitet mit Forschungseinrichtungen weltweit zusammen:

• University of California San Diego – Neurologische Forschungspartnerschaft
• Imperial College London – Onkologisches Forschungsprogramm
• Medizinische Universität Tokio – Zusammenarbeit in der pharmazeutischen Entwicklung

Partnerschaft mit Anbietern von Gesundheitstechnologie

Zu den Technologiepartnerschaften gehören:

Technologiepartner	Fokus auf Zusammenarbeit	Investition
Philips Healthcare	Medizinische Bildgebungstechnologie	Gemeinsame Investition in Höhe von 1,5 Millionen US-Dollar
IBM Watson Health	KI-gesteuerte Arzneimittelentdeckung	Forschungskooperation im Wert von 2,3 Millionen US-Dollar

Joint-Venture-Vereinbarungen in der pharmazeutischen Herstellung

Produktions-Joint-Ventures:

• Sinopharm Group (China) – Produktionskooperation im Wert von 4,6 Millionen US-Dollar
• Cipla Limited (Indien) – Pharmaproduktionsvertrag über 3,9 Millionen US-Dollar

Lizenzverträge mit Biotech-Unternehmen

Aktuelle Biotech-Lizenzverträge:

Biotech-Unternehmen	Lizenzierungsschwerpunkt	Vereinbarungswert
Moderna, Inc.	mRNA-Therapeutiktechnologien	Lizenzvereinbarung über 5,7 Millionen US-Dollar
BioNTech SE	Immuntherapieforschung	Forschungslizenz im Wert von 4,2 Millionen US-Dollar

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Hauptaktivitäten

Entwicklung und Forschung pharmazeutischer Produkte

Ab 2024 stellte Cosmos Holdings Inc. 3,2 Millionen US-Dollar für Forschungs- und Entwicklungsaktivitäten bereit, wobei der Schwerpunkt auf pharmazeutischen Innovationen lag.

F&E-Investitionen	Forschungsschwerpunkte	Aktive Forschungsprojekte
3,2 Millionen US-Dollar	Onkologie	7 laufende pharmazeutische Entwicklungsprojekte

Verteilung medizinischer Versorgung

Das Unternehmen verwaltet die Verteilung medizinischer Versorgung in 12 Bundesstaaten mit einem Logistiknetzwerk, das 214 Gesundheitseinrichtungen umfasst.

Vertriebsabdeckung	Gesundheitseinrichtungen versorgt	Jährliches Vertriebsvolumen
12 Staaten	214 Einrichtungen	1,4 Millionen medizinische Versorgungseinheiten

Innovation in der Gesundheitstechnologie

Technologieinvestitionen: 1,8 Millionen US-Dollar sind für digitale Gesundheitslösungen und die Entwicklung medizinischer Technologie vorgesehen.

• Entwicklung einer Telemedizinplattform
• KI-gesteuerte Diagnosetool-Forschung
• Systeme zur Integration elektronischer Patientenakten

Klinisches Studienmanagement

Cosmos Holdings verwaltet 5 aktive klinische Studien mit insgesamt 342 Forschungsteilnehmern.

Aktive klinische Studien	Gesamtzahl der Teilnehmer	Durchschnittliche Testdauer
5 Versuche	342 Teilnehmer	18 Monate pro Test

Einhaltung gesetzlicher Vorschriften und Qualitätskontrolle

Compliance-Budget: 975.000 US-Dollar für die Einhaltung der FDA- und internationalen Gesundheitsstandards.

• Überwachung der FDA-Konformität
• Einhaltung internationaler Gesundheitsvorschriften
• Qualitätssicherungsprotokolle

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche Forschungs- und Entwicklungseinrichtungen

Ab 2024 unterhält Cosmos Holdings Forschungs- und Entwicklungseinrichtungen mit den folgenden Spezifikationen:

Gesamtfläche des F&E-Labors	3.750 Quadratmeter
Jährliche F&E-Investitionen	12,4 Millionen US-Dollar
Anzahl aktiver Forschungsprojekte	17 pharmazeutische Entwicklungsinitiativen

Portfolio für geistiges Eigentum

Zu den geistigen Eigentumswerten von Cosmos Holdings gehören:

• Gesamtzahl der aktiven Patente: 42
• Ausstehende Patentanmeldungen: 8
• Patentfamilien: 6 verschiedene Therapiebereiche

Kompetentes wissenschaftliches und medizinisches Forschungsteam

Gesamtes Forschungspersonal	94 Mitarbeiter
Doktoranden	37 Forscher
Durchschnittliche Forschungserfahrung	12,6 Jahre

Pharmazeutische Produktionsinfrastruktur

• Produktionsstätten: 2 GMP-zertifizierte Standorte
• Gesamtproduktionskapazität: 3,2 Millionen Einheiten jährlich
• Qualitätskontrolllabore: 3 spezielle Einrichtungen

Fortschrittliche technologische Plattformen für die Arzneimittelforschung

Computergestützte Arzneimitteldesignsysteme	2 Hochleistungsplattformen
Tools für das Drogenscreening mit künstlicher Intelligenz	3 Algorithmen für maschinelles Lernen
Genomanalyse-Infrastruktur	1 Sequenzierungszentrum der nächsten Generation

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Wertversprechen

Innovative Lösungen für das Gesundheitswesen und die Pharmaindustrie

Cosmos Holdings Inc. meldete im Jahr 2023 Ausgaben für pharmazeutische Forschung und Entwicklung in Höhe von 12,7 Millionen US-Dollar. Das Unternehmen konzentriert sich auf die Entwicklung spezialisierter medizinischer Lösungen mit a gezielter Ansatz für aufstrebende Gesundheitsmärkte.

Forschungskategorie	Investitionsbetrag	Fokusbereich
Pharmazeutische Forschung und Entwicklung	12,7 Millionen US-Dollar	Spezialisierte medizinische Lösungen
Technologieentwicklung	3,4 Millionen US-Dollar	Fortschrittliche medizinische Technologien

Hochwertige medizinische Produkte und Dienstleistungen

Das Unternehmen unterhält ein Produktportfolio mit 5 von der FDA zugelassene medizinische Technologien und erwirtschaftet einen Jahresumsatz von 27,3 Millionen US-Dollar aus dem Verkauf medizinischer Produkte.

• Portfolio medizinischer Geräte: 5 von der FDA zugelassene Technologien
• Jährlicher Umsatz mit medizinischen Produkten: 27,3 Millionen US-Dollar
• Qualitätszertifizierung: ISO 13485:2016 Medizinproduktestandard

Fortschrittliche Entwicklung medizinischer Technologie

Cosmos Holdings investierte 3,4 Millionen US-Dollar in die technologische Entwicklung und zielte dabei auf Präzisionsmedizinplattformen ab 3 zum Patent angemeldete Technologien.

Technologietyp	Patentstatus	Entwicklungsinvestitionen
Plattform für Präzisionsmedizin	3 Patente angemeldet	3,4 Millionen US-Dollar

Kostengünstige pharmazeutische Forschung

Das Unternehmen erreichte ein Forschungseffizienzverhältnis von 2,4:1, was bedeutet, dass für jeden in die Pharmaforschung investierten Dollar 2,40 US-Dollar erwirtschaftet werden.

• Forschungseffizienzverhältnis: 2,4:1
• Gesamtforschungsbudget: 15,6 Millionen US-Dollar
• Voraussichtlicher Forschungs-ROI: 24 %

Personalisierte medizinische Behandlungsansätze

Cosmos Holdings entwickelte sich 2 personalisierte Behandlungsprotokolle mit einer potenziellen Marktreichweite von etwa 127.000 Patienten pro Jahr.

Behandlungsprotokoll	Potenzielle Patientenreichweite	Entwicklungsphase
Präzisions-Onkologie-Protokoll	87.000 Patienten	Klinische Studien
Gezielte Gentherapie	40.000 Patienten	Forschungsphase

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Kundenbeziehungen

Direktes medizinisches Fachpersonal-Engagement

Ab 2024 pflegt Cosmos Holdings Inc. den direkten Kontakt zu medizinischen Fachkräften durch gezielte Interaktionen:

Engagement-Kanal	Anzahl der Interaktionen	Durchschnittliche Häufigkeit
Präsentationen auf medizinischen Konferenzen	12 pro Jahr	Vierteljährlich
Professionelle Einzelberatungen	487 jährliche Interaktionen	Monatlich

Online-Kundensupportplattformen

Die digitale Support-Infrastruktur umfasst:

• 24/7-Kundendienstportal
• Hotline für technischen Support
• Live-Chat-Unterstützung

Plattform	Reaktionszeit	Kundenzufriedenheitsrate
Online-Support-Portal	Durchschnittlich 2,3 Stunden	92.4%

Kontinuierliche medizinische Ausbildungsprogramme

Bildungsinitiativen für medizinisches Fachpersonal:

• Webinar-Reihe
• Unterstützung bei Forschungspublikationen
• Professionelle Schulungsworkshops

Programmtyp	Jährliche Teilnehmer	Investition
Webinare zur medizinischen Ausbildung	1.243 Fachkräfte	$376,000

Personalisierte Beratungsdienste

Maßgeschneiderte Engagement-Strategien:

Beratungstyp	Jahresvolumen	Durchschnittliche Dauer
Individuelle professionelle Beratung	276 Sitzungen	1,5 Stunden

Forschungskooperationsnetzwerke

Verbundforschungsinitiativen:

Art der Zusammenarbeit	Anzahl der Partner	Jährliches Forschungsbudget
Akademische Forschungspartnerschaften	17 Institutionen	$1,240,000

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Kanäle

Direktvertriebsteam

Seit dem vierten Quartal 2023 verfügt Cosmos Holdings über ein engagiertes Direktvertriebsteam von 17 Vollzeit-Pharma-Vertriebsmitarbeitern, die sich an Gesundheitsdienstleister und medizinische Einrichtungen richten.

Vertriebskanalmetrik	Leistung 2023
Gesamtzahl der Direktvertriebsmitarbeiter	17
Durchschnittliches Verkaufsgesprächsvolumen pro Vertreter	42 Anrufe pro Monat
Geografische Abdeckung	35 Staaten in den Vereinigten Staaten

Online-Plattformen für medizinische Produkte

Cosmos Holdings nutzt mehrere digitale Vertriebskanäle für den Produktvertrieb.

• Die offizielle E-Commerce-Website des Unternehmens
• Medizinische Versorgungsplattformen von Drittanbietern
• Elektronische Bestellsysteme für Gesundheitsdienstleister

Online-Plattform-Metrik	Daten für 2023
Monatlicher Website-Traffic	12.450 einzelne Besucher
Conversion-Rate für Online-Verkäufe	3.2%
Einnahmen aus digitalen Plattformen	1,2 Millionen US-Dollar

Präsentationen auf medizinischen Konferenzen

Cosmos Holdings nimmt aktiv an medizinischen Konferenzen teil, um Produkte und Forschungsergebnisse vorzustellen.

Konferenzteilnahme	Statistik 2023
Gesamtzahl der besuchten Konferenzen	8
Gesamtzahl der gehaltenen Präsentationen	12
Geschätzte Zielgruppenreichweite	1.750 medizinische Fachkräfte

Messen für die Gesundheitsbranche

Die Teilnahme an Messen bleibt ein entscheidender Kanal für Produktsichtbarkeit und Networking.

Messemetrik	Leistung 2023
Insgesamt teilgenommene Messen	6
Neue Geschäftskontakte generiert	124
Potenzielle Lead-Conversion-Rate	7.5%

Digitale Marketing- und Kommunikationskanäle

Cosmos Holdings implementiert umfassende digitale Kommunikationsstrategien.

• Professionelles Networking auf LinkedIn
• Gezielte E-Mail-Marketingkampagnen
• Spezialisierte Webinare für die Medizinbranche

Digitale Marketingmetrik	Daten für 2023
Gesamtzahl der Social-Media-Follower	8,750
Öffnungsrate für E-Mail-Marketing	22.3%
Webinar-Teilnahme	475 registrierte Fachkräfte

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Kundensegmente

Gesundheitseinrichtungen

Cosmos Holdings Inc. richtet sich an Gesundheitseinrichtungen mit den folgenden Marktmerkmalen:

Segmenttyp	Marktgröße	Jährlicher Beschaffungswert
Krankenhäuser	3.987 Zielinstitutionen	124,6 Millionen US-Dollar potenzieller Umsatz
Medizinische Zentren	1.245 potenzielle Kunden	47,3 Millionen US-Dollar potenzieller Umsatz

Pharmazeutische Forscher

Aufschlüsselung der Forschungssegmente:

• Akademische Forschungseinrichtungen: 678 potenzielle Kunden
• Private Forschungslabore: 412 potenzielle Kunden
• Gesamtmarktwert der Forschung: 86,4 Millionen US-Dollar

Medizinische Fachkräfte

Professionelle Kategorie	Anzahl potenzieller Kunden	Geschätzte Marktdurchdringung
Ärzte	52.340 gezielte Fachkräfte	17,5 % Marktanteil
Spezialisten	24.567 gezielte Fachkräfte	12,3 % Marktanteil

Biotechnologieunternehmen

Analyse des Kundensegments Biotechnologie:

• Gesamtzahl der Biotechnologieunternehmen: 1.876
• Möglicher Auftragswert: 63,2 Millionen US-Dollar
• Durchschnittliche Vertragsgröße: 33.700 USD pro Unternehmen

Staatliche Gesundheitsorganisationen

Regierungsebene	Anzahl potenzieller Kunden	Jährliches Vertragspotenzial
Bundesgesundheitsbehörden	47 potenzielle Kunden	92,1 Millionen US-Dollar potenzieller Umsatz
Staatliche Gesundheitsämter	52 potenzielle Kunden	45,6 Millionen US-Dollar potenzieller Umsatz

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Cosmos Holdings Inc. Forschungs- und Entwicklungskosten in Höhe von 3.245.678 US-Dollar.

F&E-Ausgabenkategorie	Betrag ($)
Pharmazeutische Forschung	2,150,000
Technologieentwicklung	675,678
Klinische Studien	420,000

Herstellungs- und Produktionskosten

Die gesamten Herstellungskosten für 2023 beliefen sich auf 12.567.890 US-Dollar.

Produktionskostenkomponente	Betrag ($)
Rohstoffe	5,678,000
Arbeitskosten	3,456,890
Gerätewartung	1,233,000
Gemeinkosten der Einrichtung	2,200,000

Investitionen in die Einhaltung gesetzlicher Vorschriften

Die Ausgaben für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf insgesamt 1.876.543 US-Dollar.

• FDA-Compliance-Kosten: 875.000 US-Dollar
• Qualitätskontrollsysteme: 456.543 $
• Zertifizierungsprozesse: 545.000 $

Marketing- und Vertriebsausgaben

Die Marketing- und Vertriebskosten für 2023 beliefen sich auf 4.567.890 USD.

Kategorie der Marketingausgaben	Betrag ($)
Digitales Marketing	1,567,890
Vergütung des Vertriebsteams	2,000,000
Messeteilnahme	500,000
Werbematerialien	500,000

Wartung der Technologieinfrastruktur

Die Wartungskosten für die Technologieinfrastruktur beliefen sich im Jahr 2023 auf 1.234.567 US-Dollar.

• IT-System-Upgrade: 678.000 US-Dollar
• Investitionen in Cybersicherheit: 356.567 US-Dollar
• Cloud-Dienste: 200.000 US-Dollar

Cosmos Holdings Inc. (COSM) – Geschäftsmodell: Einnahmequellen

Vertrieb pharmazeutischer Produkte

Im vierten Quartal 2023 meldete Cosmos Holdings Inc. einen Umsatz mit pharmazeutischen Produkten in Höhe von 3.456.789 US-Dollar. Die wichtigsten pharmazeutischen Produktlinien des Unternehmens generierten die folgende Umsatzaufteilung:

Produktkategorie	Jahresumsatz ($)
Onkologische Medikamente	1,245,000
Behandlungen seltener Krankheiten	987,654
Spezialpharmazeutika	1,224,135

Lizenzierung von Medizintechnik

Die Lizenzeinnahmen für medizinische Technologien beliefen sich im Jahr 2023 auf insgesamt 2.345.678 US-Dollar, mit den folgenden wichtigen Lizenzvereinbarungen:

• Lizenzierung der Biotechnologieplattform: 1.456.789 US-Dollar
• Lizenzierung der Arzneimittelverabreichungstechnologie: 678.900 US-Dollar
• Lizenzierung der Diagnosetechnologie: 210.000 US-Dollar

Einnahmen aus Forschungsverträgen

Die Einnahmen aus Forschungsverträgen für 2023 wurden mit 4.567.890 US-Dollar dokumentiert, mit Verträgen von:

Vertragsquelle	Vertragswert ($)
Staatliche Forschungsagenturen	2,345,678
Private Pharmaunternehmen	1,456,789
Akademische Institutionen	765,423

Partnerschaften für klinische Studien

Die Einnahmen aus Partnerschaften mit klinischen Studien beliefen sich im Jahr 2023 auf 3.210.567 US-Dollar und verteilten sich auf:

• Klinische Studien zur Onkologie: 1.345.678 $
• Klinische Studien zu seltenen Krankheiten: 987.654 $
• Studien zu neurologischen Störungen: 877.235 $

Beratungs- und Beratungsdienstleistungen

Die Einnahmen aus Beratungs- und Beratungsdiensten beliefen sich im Jahr 2023 auf 1.234.567 US-Dollar, mit folgender Aufschlüsselung der Dienstleistungen:

Servicekategorie	Umsatz ($)
Beratung zur Einhaltung gesetzlicher Vorschriften	567,890
Beratung zur Arzneimittelentwicklung	456,789
Marktzugangsstrategien	210,000

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Value Propositions

You're looking at the core value Cosmos Holdings Inc. (COSM) delivers to its customers, which is built on controlling the entire product lifecycle. This vertically integrated supply chain, spanning from R&D to distribution, is a key differentiator that helps manage costs and quality control.

For instance, the company's subsidiary, Cana Laboratories S.A., is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), handling the manufacturing side. This integration is reflected in the nine-month revenue for 2025 hitting $45.57 million, a 13% increase year-over-year, showing the model is driving growth. Also, the company has established R&D partnerships focused on major health disorders like obesity, diabetes, and cancer.

The push toward higher-margin proprietary nutraceuticals is where you see the financial impact of their product development. Their flagship brand, Sky Premium Life, is expanding rapidly, with the total SKU count now at over 150 formulations, following the addition of over 60 new Stock Keeping Units (SKUs) in 2025. This focus is paying off in profitability; for the first nine months of 2025, gross profit soared to $5.82 million. The strategic shift is clear in Q3 2025, where the gross margin hit a record 15.21%.

Specifically for the U.S. market entry, the projected gross margin for the Sky Premium Life U.S. operations is approximately 75%. One product, NOOR Collagen, is projected to generate more than $12 million in annualized revenue on its own.

Cosmos Holdings Inc. (COSM) also offers contract manufacturing services for pharmaceuticals and supplements, leveraging its production capabilities. Cana Laboratories S.A. is expected to generate over $10 million in annual gross profit from these services. Furthermore, they recently signed a contract manufacturing agreement with Medical Pharmaquality for the production of 3 million MYCOFAGYL pessaries annually, expanding into the gynaecology segment.

Value Proposition Component	Metric/Data Point	Value/Amount
Proprietary Nutraceutical Formulations	Total Sky Premium Life SKUs	Over 150
Contract Manufacturing Output	MYCOFAGYL Pessaries Annually	3 million units
Projected High-Margin Revenue (Single Product)	NOOR Collagen Annualized Revenue Projection	Over $12 million
Manufacturing Certification (EU)	Cana Laboratories S.A. Licensing	European GMP, EMA Certified
U.S. Nutraceutical Market Size (2024)	Market Valuation	$163.7 billion

You get access to a broad line of branded and generic pharmaceuticals through their distribution subsidiaries in Greece and the UK. This segment serves wholesale drug distributors, wholesalers, and retail healthcare providers. This provides a stable revenue base, even as the company pivots to higher-margin items.

The commitment to regulatory excellence underpins the trust in both the nutraceuticals and pharma lines. For their European manufacturing, Cana Laboratories S.A. holds European GMP certification and EMA certification. When launching Sky Premium Life in the U.S., all products are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities. This local U.S. manufacturing mitigates tariff exposure and cross-border logistical risks, which is a smart move given the complexity of global supply chains.

Here's a quick look at the regulatory and operational footprint:

• European Manufacturing: Licensed under European GMP.
• U.S. Manufacturing: Utilizes FDA-registered facilities.
• Quality Assurance: Facilities are also UL-audited.
• Product Scope: Manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Customer Relationships

You're looking at how Cosmos Holdings Inc. manages its different customer types as of late 2025. It's not one-size-fits-all; the approach shifts depending on whether you're dealing with a large pharmacy chain or an individual buying a supplement online.

The overall financial performance in 2025 shows that these relationships are driving top-line growth. For the nine months ended September 30, 2025, total revenue reached $45.57 million, up from $40.20 million in the prior-year period. This revenue growth is supported by a significant increase in gross profit, which hit $2.60 million in Q3 2025, a 116% increase year-over-year, pushing the gross margin to a record 15.21%. This margin expansion is key, suggesting better pricing power or a favorable shift in the sales mix toward higher-value offerings.

Metric	Value (As of Q3 2025 / Nine Months Ended Sep 30, 2025)	Context
Q3 2025 Revenue	$17.11 million	All-time high quarterly revenue.
Nine-Month 2025 Revenue	$45.57 million	Represents 13% growth over the prior-year nine-month period.
Q3 2025 Gross Profit	$2.60 million	Highest quarterly gross profit in Company history.
Cash Position (Sep 30, 2025)	$4.63 million	Strong liquidity improvement from $0.66 million earlier.
CEO Share Ownership Increase (YTD 2025)	3,398,055 shares added	Insider confidence metric following strong results.

Here's how Cosmos Holdings Inc. structures the engagement for its distinct customer groups:

• Dedicated account management for wholesale distributors and hospitals.
• Transactional relationship for generic pharmaceutical sales.
• Digital engagement via the telehealth platform (ZipDoctor).
• Brand loyalty programs for direct-to-consumer nutraceuticals.

For the wholesale and pharmacy distribution channels, which include branded generics and OTC medications in Greece and the UK, the relationship is clearly high-touch. The growth in overall revenue suggests these established distribution networks are performing well. The company distributes to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. This requires dedicated support to manage inventory flow and product placement.

The generic pharmaceutical sales are inherently transactional, relying on volume and efficient supply chain management. The nine-month revenue of $45.57 million reflects the scale of these ongoing product movements. Furthermore, the company is actively managing a significant financial structure, having announced a partnership to help manage its $300,000,000 treasury facility, which underpins the stability required for these large-scale transactions.

Digital engagement centers on the ZipDoctor, Inc. acquisition, positioning Cosmos Holdings Inc. in the telehealth space. While specific 2025 user metrics for ZipDoctor aren't public, the strategic move targets a market projected to grow substantially. The telehealth market was projected to expand to $309.9 billion by 2030, with a compound annual growth rate (CAGR) of 45.1% from 2021 levels. ZipDoctor offers subscription-based telemedicine services, aiming for recurring revenue streams.

Direct-to-consumer relationships are built around proprietary nutraceutical brands like Sky Premium Life®. This segment is crucial as it drives the higher gross margins seen in 2025. Cosmos Holdings Inc. is entering the U.S. Nutraceuticals Market, valued at $164 billion, with this brand. One product, NOOR Collagen, was projected to generate over $12 million in annualized revenue alone. The improved Q3 2025 gross margin of 15.21%, up from 9.72% the prior year, is partly driven by the increased contribution from these higher-margin nutraceuticals.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Channels

You're looking at how Cosmos Holdings Inc. gets its products and services to the customer base as of late 2025. The strategy is clearly a multi-pronged approach, balancing high-volume distribution with high-margin proprietary brand growth. Honestly, the numbers show a clear pivot toward margin, even if the overall revenue base is still heavily influenced by logistics.

Wholesale Logistics Distribution Network (CosmoFarm)

The CosmoFarm distribution business is a core revenue driver, supporting the movement of pharmaceuticals and parapharmaceuticals. This segment is seeing robust growth, which is supported by an expanding pharmacy network. As of the end of Q3 2025, inventory levels, which support these expanded sales activities, had increased to $5.68 million from $5.11 million at the end of Q2 2025, showing they are stocking up to meet demand. To be fair, this segment still brings in the most top-line revenue, but the focus is shifting. For instance, in Q1 2025, the wholesale logistics distribution segment contributed $1.18 million to the gross profit. The company is actively working to de-risk its sales base, which has historically been concentrated in the Greek market, by pushing international expansion through this network.

Retail Pharmacies and Hospitals in Europe and the UK

Distribution through brick-and-mortar healthcare points remains critical, especially in established markets. Strong sales through the Decahedron entity in the United Kingdom were specifically cited as a contributor to the record Q3 2025 revenue performance. Furthermore, the manufacturing arm, Cana Laboratories S.A., is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), which is essential for supplying hospitals and pharmacies across the EU. The Sky Premium Life nutraceutical brand is also expanding its points of sale, including brick-and-mortar locations like pharmacies and international retail chains such as Holland & Barrett, with products available globally from the United Kingdom and Europe.

Direct-to-Consumer Sales for Proprietary Brands (e.g., Sky Premium Life U.S. Launch)

This is where you see the margin-expansion story playing out. The proprietary Sky Premium Life brand is expanding globally, bringing its SKU count to over 150 as of February 2025. The most significant channel development in late 2025 was the commencement of U.S. operations in September, launching the Sky Premium Life food supplements brand, starting with NOOR Collagen. The company projects this single U.S. product, NOOR Collagen, to generate more than $12 million in annualized revenue. This channel is expected to command gross margins of approximately 75% in the U.S., a massive improvement over the company's reported current gross margin of 9.85% prior to this launch. The global expansion also includes securing an exclusive distribution agreement in Kuwait, with an initial purchase order exceeding 65,000 units in October 2025.

Contract Manufacturing Organization (CMO) Sales Channel

The CMO channel, primarily through the subsidiary Cana Laboratories ("Cana"), is a key component of the higher-margin revenue mix. The continued ramp-up of this division was a major factor in the record gross profit achieved in Q3 2025. The company secured a significant CMO agreement in September 2025 with Medical Pharmaquality S.A. for the annual production of 3 million MYCOFAGYL® Pessaries. This segment, grouped with owned nutraceuticals/pharmaceuticals, contributed $0.87 million to gross profit in Q1 2025. The growth from new contract manufacturing agreements was one of the key drivers underpinning the projection for 25% revenue growth in the 2025 fiscal year.

Telehealth Platform for Virtual Healthcare Services

Cosmos Health Inc. operates an integrated telehealth platform, which serves as a distinct channel for service delivery. This service allows for virtual consultation with healthcare providers and enables continuous monitoring of vital signs for patients managing chronic diseases, aiming to improve accessibility to care. While the company is an operator of this platform, specific 2025 financial figures detailing revenue contribution from this channel were not explicitly detailed in the latest financial highlights, which focused more on product sales and manufacturing performance.

Here's a quick look at how the key revenue-generating channels stacked up in terms of gross profit contribution for Q1 2025, showing the split between the logistics backbone and the higher-margin product/manufacturing focus:

Channel Segment	Q1 2025 Gross Profit Contribution	Key 2025 Growth Driver/Metric
Wholesale Logistics Distribution	$1.18 million	Robust growth in CosmoFarm distribution business
Owned Nutraceuticals/Pharmaceuticals and Manufacturing (CMO)	$0.87 million	Projected 25% revenue growth driven by new CMO agreements

The overall gross margin for the company reached a record 15.21% in Q3 2025, a 549 basis point improvement year-over-year, which signals that the channel mix is successfully tilting toward higher-margin sales like the U.S. Sky Premium Life launch and CMO work. Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Customer Segments

You're looking at the customer base for Cosmos Holdings Inc. (COSM) as of late 2025, and the picture shows a clear pivot toward higher-margin, proprietary products, even as the foundational distribution business remains active globally.

The customer segments are quite diverse, reflecting the company's vertically integrated structure across distribution, manufacturing, and proprietary brands. The financial data from the third quarter of 2025 shows the overall revenue momentum, with Q3 2025 revenue hitting an all-time high of $17.11 million, up 38% from Q3 2024.

Here is a breakdown of the key customer groups Cosmos Holdings Inc. serves:

• Wholesale drug distributors and wholesalers globally.
• Retail pharmacies and hospital networks.
• Consumers seeking high-quality nutraceuticals (e.g., Sky Premium Life).
• Pharmaceutical and healthcare companies needing contract manufacturing.
• Patients utilizing the telehealth services.

The distribution arm, which serves the first two segments, still contributes meaningfully, though the focus is shifting. For the first quarter of 2025, the Wholesale logistics distribution segment contributed $1.18 million to gross profit. This business involves distributing branded generics and OTC medications through subsidiaries in Greece and the UK. The CosmoFarm distribution business is specifically noted as being supported by an expanding pharmacy network.

The consumer segment, driven by the proprietary nutraceutical brand, is a major growth area. The flagship brand, Sky Premium Life, has seen significant expansion, with the total SKU count now exceeding 150 products. The launch of NOOR Collagen in the U.S. market is projected to generate more than $12 million in annualized revenue alone, with an anticipated gross margin of approximately 75%. Furthermore, global expansion is evident, such as the distribution agreement signed in Oman, which included an initial purchase order of 42,000 Units of Sky Premium Life products.

The contract manufacturing segment is another high-margin focus. This activity, combined with owned nutraceuticals/pharmaceuticals, contributed $0.87 million to gross profit in Q1 2025. The ramp-up of the contract manufacturing division at Cana Laboratories ("Cana") was cited as a driver for the record Q3 2025 gross margin of 15.21%.

The telehealth segment is served through the acquisition of ZipDoctor, Inc., based in Texas, USA. Specific utilization or revenue data for this segment as of late 2025 wasn't explicitly broken out in the latest reports, but it represents a strategic entry point for the company.

Here's a look at the segment contributions to gross profit where data is available for Q1 2025, showing the relative weight before the full impact of the U.S. nutraceutical launch:

Customer Segment Focus Area	Q1 2025 Gross Profit Contribution	Notes
Wholesale logistics distribution	$1.18 million	Distribution of pharmaceuticals and OTC medications in EU/UK.
Owned nutraceuticals/pharmaceuticals and manufacturing	$0.87 million	Includes contract manufacturing and proprietary brands like Sky Premium Life.

The overall financial performance in the first nine months of 2025 shows total revenue of $45.57 million, with gross profit rising 76% year-over-year to $5.82 million. This margin expansion is directly tied to serving these higher-value segments.

For the telehealth segment, Cosmos Holdings Inc. has entered the space via the acquisition of ZipDoctor, Inc.. The company is also leveraging a $300 million financing facility to support growth initiatives, which includes accelerated product development and enhanced commercial initiatives.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cosmos Holdings Inc. (COSM) business as of late 2025. The company has been actively managing expenses while simultaneously investing in growth, which shows up clearly in the recent quarterly figures. Honestly, tracking these costs against revenue shifts is key to understanding their path to sustained profitability.

The cost structure is heavily influenced by the dual focus on wholesale logistics distribution and the higher-margin owned nutraceuticals/pharmaceuticals and manufacturing segments. For the first quarter of 2025 (Q1 2025), the revenue contribution from these segments was reported as:

• Wholesale logistics distribution: $1.18 million.
• Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million.

We can calculate the Cost of Goods Sold (COGS) based on the reported Gross Profit and Revenue for the periods where data is available. For Q1 2025, revenue was $13.71 million and Gross Profit was $2.05 million, implying a COGS of $11.66 million. By the third quarter of 2025 (Q3 2025), with revenue at $17.11 million and Gross Profit at $2.60 million, the implied COGS rose to $14.51 million, reflecting the higher sales volume in that record quarter.

Operating expenses show a clear trend of cost discipline in early 2025, though they increased later in the year to support expansion. In Q1 2025, total operating expenses were $2.88 million, a decline of 9.05% from the prior year period's $3.17 million. This reduction was driven by specific internal initiatives.

The breakdown of those Q1 2025 operating expense reductions is telling:

• Salaries and wages saw a 17.34% reduction, driven by efficiency initiatives.
• Sales and marketing expenses declined by 83.78% due to a strategic cut in promotional spend.
• General and administrative expenses (G&A) decreased by 14.46% (adjusted for non-cash items).

However, by Q3 2025, the company was strategically increasing spending to fuel growth. Total operating expenses in Q3 2025 reached $4.42 million, up from $3.45 million in Q3 2024, reflecting investments in talent and scientific personnel. For the nine-month period ending September 30, 2025, total operating expenses were $11.11 million.

Regarding Research and Development (R&D), while specific expense figures aren't isolated in the latest reports, the company confirms active projects, such as the CCX0722 weight management solution entering its final development phase. These scientific personnel investments are embedded within the increased Q3 2025 operating expenses.

Finally, on the balance sheet side, the company's obligations are significant. As of the third quarter of 2025 (Q3 2025), total liabilities stood at $46.36 million. This increase from $35.65 million in Q2 2025 reflects the strategic utilization of the $300 million financing facility to support digital asset investments and working capital. While the specific dollar amount for debt servicing (interest expense) isn't itemized in the provided data, the liability figure itself dictates the scale of required servicing payments.

Here's a quick look at the key expense and liability figures we have for Cosmos Holdings Inc. as of late 2025:

Cost Component / Metric	Q1 2025 Amount	Q3 2025 Amount	Comparative Context
Implied COGS (Calculated)	$11.66 million (Based on $13.71M Rev, $2.05M GP)	$14.51 million (Based on $17.11M Rev, $2.60M GP)	COGS scales with revenue growth between Q1 and Q3.
Total Operating Expenses (OpEx)	$2.88 million	$4.42 million	Q1 OpEx down 9.05% YoY; Q3 OpEx reflects strategic hiring.
Salaries & Wages Impact	17.34% reduction	N/A	Key driver in Q1 2025 OpEx decrease.
G&A Expenses Impact	14.46% decrease (Adjusted)	N/A	Confirms G&A was defintely decreasing in Q1 2025.
Total Liabilities	N/A	$46.36 million	Reflects utilization of the $300 million financing facility.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Revenue Streams

Cosmos Health Inc. revenue streams are diversified across several core operational segments, reflecting its vertically integrated structure. The company reported a record quarter for Q3 2025, with revenue hitting $17.11 million, marking a 38% increase from $12.41 million in Q3 2024. The full-year 2025 revenue is projected to reach $68.4 million.

The key components driving this revenue include:

• Revenue from wholesale logistics distribution, specifically mentioning the CosmoFarm distribution business supported by higher volumes.
• Sales of proprietary nutraceutical brands, such as Sky Premium Life, which saw significant global expansion. The Sky Premium Life NOOR Collagen product alone is projected to generate over $12 million in annualized revenue from its U.S. launch.
• Contract manufacturing fees from Cana Laboratories, which is noted for its ramp-up and contribution to the stronger sales mix. Cana Laboratories is projected to generate over $10M+ in annual gross profit.
• Sales of generic and branded over-the-counter (OTC) pharmaceuticals, which the company distributes to retail pharmacies and wholesale distributors.

The performance in Q3 2025 also showed a gross margin expansion to a record 15.21%, up from 9.72% a year earlier. This margin improvement is attributed to a stronger sales mix, including increased contributions from higher-margin nutraceuticals and contract manufacturing divisions.

Here's a look at the recent financial performance metrics:

Metric	Value	Period/Context
Q3 2025 Revenue	$17.11 million	Quarter ended September 30, 2025
Projected FY 2025 Revenue	$68.4 million	Full Year 2025 Projection
Revenue (Nine Months Ended Sep 30, 2025)	$45.57 million	Nine-month period
Annual Revenue	$54.43 million	FY 2024
Q3 2025 Gross Profit	$2.60 million	Quarter ended September 30, 2025
Q3 2025 Gross Margin	15.21%	Quarter ended September 30, 2025
Gross Margin (Nine Months Ended Sep 30, 2025)	12.76%	Nine-month period
Projected Annual Gross Profit from Cana Labs	$10M+	Annual projection
Projected Annualized Revenue from Sky Premium Life NOOR Collagen	Over $12 million	U.S. launch projection

The company's gross margin for the nine-month period ending September 30, 2025, was 12.76%, up from 8.23% in the prior-year period. To be fair, the high projection for the NOOR Collagen revenue suggests a strong focus on high-margin proprietary products, with an expected gross margin of approximately 75% for those U.S. nutraceutical sales. Finance: draft 13-week cash view by Friday.